Development of an in-vivo active reversible butyrylcholinesterase inhibitor. - Université Grenoble Alpes Accéder directement au contenu
Article Dans Une Revue Scientific Reports Année : 2016

Development of an in-vivo active reversible butyrylcholinesterase inhibitor.

Urban Košak
  • Fonction : Auteur
Boris Brus
  • Fonction : Auteur
Damijan Knez
  • Fonction : Auteur
Roman Šink
  • Fonction : Auteur
Anja Pišlar
  • Fonction : Auteur
Jasna Šlenc
  • Fonction : Auteur
Kinga Sałat
  • Fonction : Auteur
Barbara Malawska
Janko Kos
  • Fonction : Auteur


Alzheimer's disease (AD) is characterized by severe basal forebrain cholinergic deficit, which results in progressive and chronic deterioration of memory and cognitive functions. Similar to acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic neurotransmission. Its enzymatic activity increases with the disease progression, thus classifying BChE as a viable therapeutic target in advanced AD. Potent, selective and reversible human BChE inhibitors were developed. The solved crystal structure of human BChE in complex with the most potent inhibitor reveals its binding mode and provides the molecular basis of its low nanomolar potency. Additionally, this compound is noncytotoxic and has neuroprotective properties. Furthermore, this inhibitor moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning abilities of mice in a model of the cholinergic deficit that characterizes AD, without producing acute cholinergic adverse effects. Our study provides an advanced lead compound for developing drugs for alleviating symptoms caused by cholinergic hypofunction in advanced AD.

Dates et versions

hal-01465678 , version 1 (13-02-2017)



Urban Košak, Boris Brus, Damijan Knez, Roman Šink, Simon Žakelj, et al.. Development of an in-vivo active reversible butyrylcholinesterase inhibitor.. Scientific Reports, 2016, 6, pp.39495. ⟨10.1038/srep39495⟩. ⟨hal-01465678⟩
186 Consultations
0 Téléchargements



Gmail Facebook X LinkedIn More